Intravitreal bevacizumab treatment for chronic central serous chorioretinopathy presumably associated with trigger point steroid injection

Basit Öğe Kaydı
dc.contributor.authorTufan, Hasan Ali
dc.contributor.authorGencer, Baran
dc.contributor.authorÇömez, Arzu Taşkiran
dc.contributor.authorÖzdek, ŞengÜl
dc.date.accessioned2025-01-27T19:04:17Z
dc.date.available2025-01-27T19:04:17Z
dc.date.issued2013
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractA 48-year-old man presented with a 6-month history of decreased visual acuity (VA) in his both eyes. There wasn't any significant medical history except an application of a steroid injection for trigger point 17 months ago. Fundus examination demonstrated atrophic changes of the retinal pigment epithelium (RPE) in the central macula OU. Optical coherence tomography showed subfoveal neurosensorial detachment adjacent to RPE detachment in the right eye and macular atrophy in the left eye. Fundus fluorescein angiography was consistent with central serous chorioretinopathy (CSC). This report describes the possible benefit of intravitreal bevacizumab in the treatment of chronic CSC complicated with trigger point steroid injection.
dc.identifier.endpage222
dc.identifier.issn1300-1256
dc.identifier.issue3
dc.identifier.scopus2-s2.0-84890364090
dc.identifier.scopusqualityQ4
dc.identifier.startpage219
dc.identifier.urihttps://hdl.handle.net/20.500.12428/13897
dc.identifier.volume21
dc.indekslendigikaynakScopus
dc.language.isoen
dc.relation.ispartofRetina-Vitreus
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_Scopus_20250125
dc.subjectChronic central serous chorioretinopathy; Intravitreal bevacizumab; Steroid; Trigger point injection
dc.titleIntravitreal bevacizumab treatment for chronic central serous chorioretinopathy presumably associated with trigger point steroid injection
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu